[1]陈平钰,李洪超,马爱霞.直接抗病毒药物治疗慢性丙型肝炎患者的预算影响分析[J].卫生经济研究,2019,(01):44-47,51.
　CHEN Ping-yu,LI Hong-chao,MA Ai-xia.Budgetary Impact Analysis of Direct Antiviral Drugs in the treatment of Patients with Chronic Hepatitis C[J].Journal Press of Health Economics Research,2019,(01):44-47,51.
点击复制

直接抗病毒药物治疗慢性丙型肝炎患者的预算影响分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年01期
页码:
44-47,51
栏目:
医保天地
出版日期:
2019-01-04

文章信息/Info

Title:
Budgetary Impact Analysis of Direct Antiviral Drugs in the treatment of Patients with Chronic Hepatitis C
作者:
陈平钰1; 李洪超1; 马爱霞1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
CHEN Ping-yu; LI Hong-chao; MA Ai-xia
International Pharmaceutical Business School of China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
直接抗病毒药物; 慢性丙型肝炎; 预算影响分析; 医保目录
Keywords:
direct antiviral drug; chronic hepatitis C; budgetary impact analysis; medical insurance catalog
分类号:
R19
文献标志码:
A
摘要:
目的：以参与城镇职工基本医疗保险的基因1b型慢性丙型肝炎患者为目标人群，对直接抗病毒药物纳入医保目录后的基金支出进行预算影响分析。方法：通过对目标人群、不同产品市场份额和医保支付金额的设定与计算，以2018年为基线年，分析今后5年内DAAs纳入医保目录对医保基金支出的影响。结果：DAAs进入医保目录后，医保基金支出增加，5年累计增幅19.63%；治愈总人数增加，5年累计增幅92.30%；DAAs医保支付标准的变化对基础结果的影响较大。结论：DAAs进入医保目录后，由于接受治疗的患者人数增加，短期内医保基金
Abstract:
Objective To analyze the budgetary impact of taking direct antiviral drugs (DAAs) into the medical insurance catalogue among patients with type 1b chronic hepatitis C who participated in urban workers' basic medical insurance. Methods Through the setting and calculation of the target population，market share of different products，and the amount of medical insurance payment，the impact of taking DAAs into the medical insurance catalogue on the expenditure of medical insurance funds in the next five years will be analyzed with 2018 as the baseline year. Results After the DAAs entered the medical insurance catalogue，the expenditure of the medical insurance fund increased，and the cumulative increase in the five years was 19.63%；the total number of cured patients increased，and the cumulative increase in the five years was 92.30%；the change in the DAAs medical insurance payment standard had a greater impact on the basic results. Conclusion After the DAAs entered the medical insurance catalogue，due to the increases in the number of patients receiving treatment，the expenditure on medical insurance funds may increase in the short term. As the stock of patients decreases，the expenditure on medical insurance funds will also decrease accordingly.

参考文献/References:

[1] 陈红松, 窦晓光, 段钟平, 等. 丙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015(12):1961-1979.
[2] DUAN Z P, ZHOU H Y, DUAN C, et al. Survey of Treatment Costs to Hepatitis C in China[J]. Value Health, 2014,17(7):A805.
[3] WHO.Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
[4] WHO.Hepatitis C[EB/OL]. http://www.who.int/mediacentre/factsheets/fs164/en/
[5] 中华人民共和国2017年国民经济和社会发展统计公报[EB/OL]. http://www.stats.gov.cn/tjsj/zxfb/201802/t20180228_1585631.html.
[6] 2017年全国法定传染病疫情概况[EB/OL]. http://www.nhfpc.gov.cn/jkj/s3578/201802/de926bdb046749abb7b0a8e23d929104.shtml.
[7] 万彬, 丁海霞, 占伊扬. 丙肝医疗费用现状及支付方式研究[J]. 中国医疗保险, 2017(10):59-61.
[8] FERREIRA V L, ASSIS J N, TONIN F S, et al. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis[J]. J Clin Pharm Ther, 2016,41(5):478-485.
[9] ZHAO S H, CHU Y L, CHENG D X, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C[J]. Int J Clin Pract, 2009,63(9):1334-1339.
[10] RAO H, LI H, CHEN H, et al. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study[J]. Journal of Gastroenterology and Hepatology, 2017,32(1):244-252.
[11] GEORGE J, BURNEVICH E, SHEEN I S, et al. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection[J]. Hepatol Commun, 2018,2(5):595-606.
[12] WEI L, WANG F S, ZHANG M X, et al. Daclatasvir plus asunaprevir in treatment-naive patients with hepatitis C virus genotype 1b infection[J]. World J Gastroenterol, 2018,24(12):1361-1372.
[13] FERENCI P, BERNSTEIN D, LALEZARI J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV[J]. N Engl J Med, 2014,370(21):1983-1992.
[14] WEI L, XIE Q, HOU J L, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China[J]. J Gastroenterol Hepatol, 2018,33(6):1168-1176.
[15] FELD J J, JACOBSON I M, HEZODE C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection[J]. N Engl J Med, 2015,373(27):2599-2607.
[16] KAO J H, TUNG S Y, LEE Y, et al. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis[J]. J Gastroenterol Hepatol, 2016,31(10):1757-1765.

更新日期/Last Update: 2019-01-04